US 11858957
Ectonucleotidase inhibitors and methods of use thereof
granted A61PA61P33/00
Quick answer
US patent 11858957 (Ectonucleotidase inhibitors and methods of use thereof) held by ANTENGENE THERAPEUTICS LIMITED expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ANTENGENE THERAPEUTICS LIMITED
- Grant date
- Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 39
- CPC classes
- A61P, A61P33/00